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OBJECTIVES: Current care in Italy for first-line treatment of seizures consists of
rectal diazepam with some use of intravenous treatments (diazepam, midazolam
and lorazepam) in a hospital setting. In the community there can be reluctance to
administer rectal diazepam due to dignity and social acceptability issues. BUCCO-
LAM (oromucosal midazolam), the first product to receive a Paediatric-Use Market-
ing Authorisation (PUMA), is approved for the treatment of prolonged, acute, con-
vulsive seizures (PACS) in children and may be used by parents and other carers. A
decision-tree model was developed to assess the cost effectiveness of BUCCOLAM
compared to rectal diazepam for the treatment of (PACS) initially occurring in the
community setting. METHODS: The model allows for different routes though the
treatment pathway that include whether or not 1) a carer administers treatment, 2)
an ambulance is required and patients are taken to hospital; and 3) inpatient stay
is re;uired. Clinical effectiveness data were obtained from McIntyre et al (2005) and
a Delphi panel. Costs were taken from published sources. The price proposed for
BUCCOLAM reimbursement to the Italian National Health Service is used. Rectal
diazepam is not reimbursable therefore its cost is not included. Estimates of the
number of seizures per year where BUCCOLAM might be used were taken from
published sources. RESULTS: Over one year, compared to rectal diazepam, BUC-
COLAM showed a reduction in per patient costs of €1,467. The largest saving came
from an estimated reduction in inpatient costs of €919 per patient per year. Patients
treated with BUCCOLAM also had a higher health related quality of life than those
treated with rectal diazepam; treatment with BUCCOLAM is therefore dominant.
CONCLUSIONS: Treatment with BUCCOLAM is cost saving, through a reduction in
the need for ambulance call outs and hospital stays, and is more socially acceptable
than treatment with rectal diazepam.
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OBJECTIVES: To evaluate the economic outcomes of three kind of interferon-beta
comparing to placebo: IM IFNb1-a, SC IFNb1-a, or SC IFNb1-b in patients diagnosed
with Relapsing-Remitting Multiple Sclerosis (RRMS). METHODS: A literature-based
Markov model was developed to assess the cost-effectiveness of three interferon-
betas with placebo for managing a hypothetical cohort of patients diagnosed with
RRMS in Iran. Health states were based on the Kurtzke Expanded Disability Status
Scale (EDSS), a widely accepted scale for assessing Multiple sclerosis. Disease pro-
gression transition probabilities for symptom management were obtained from
natural history studies. Treatment effects of the interferon-beta therapies were
taken from related multicenter randomized controlled trials and their long term
follow up for RRMS and Secondary progressive Multiple Sclerosis (SPMS). Transi-
tion probabilities were adjusted to account for treatment discontinuation and age
and sex adjusted death rate. Transitions among health states occurred in 2-years
cycles for fifteen cycles. Only medical direct cost has been considered for
evaluation. RESULTS: The incremental cost per quality-adjusted life-year for IM
IFNb1-a therapies is $474,819, and dominated for SC IFNb1-a, or SC IFNb1-b com-
pared with placebo. The incremental cost per prevention of utility loss due to
relapses is $144912, $117455, $185907, for IM IFNb1-a, SC IFNb1-a, or SC IFNb1-b
respectively compared with placebo. CONCLUSIONS: The Markov pharmacoeco-
nomics model determined that SC IFNb1-a was the best strategy of the 3 interferon-
beta therapies used to manage MS in term of relapse, however none of these med-
icines were cost-effective considering progression of disease and utilities or
avoiding utility loss due to relapses.
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OBJECTIVES: In the UK, two treatment options are used for acute epileptic seizures
in the community – rectal diazepam (RD) and unlicensed oromucosal midazolam
(UOM). In practice the former is rarely used, with UOM being widely recommended
by physicians and prescribed unlicensed. In September 2011, Buccolam (licensed
oromucosal midazolam) became the first product to receive a paediatric-use mar-
keting authorisation (PUMA) and is indicated for the treatment of prolonged, acute,
convulsive seizures in children (3 months to 18 years). To support the successful
submission to the Scottish Medicines Consortium, a model was constructed as-
sessing the cost-effectiveness of Buccolam for such seizures initially occurring in
the community setting. METHODS: A hybrid model was developed, including a
time-to-event simulation for the frequency and location of occurrence of seizures
along with a decision tree model that assessed the treatment pathway when a child
has a seizure. The model was informed by data from a variety of sources including
clinical effectiveness estimates from McIntyre et al. 2005 and costs based on pub-
lished Scottish data where possible. To determine current practice, a Delphi panel,
hospital audit and survey of parents of children with epilepsy were conducted. A
6-year time horizon was used in the base case. The associated cost and health-
related quality-of-life (HRQL) impacts were calculated and scenario analyses were
conducted to assess the robustness of the model. RESULTS: Buccolam showed a
reduction in costs when compared to UOM or RD: £2,046 and £8,516, respectively. It
also improved HRQL showing an increase of 0.005 and 0.036 quality adjusted life
years, respectively. Buccolam remained dominant across a range of scenario
analyses. CONCLUSIONS: Cost savings associated with treatment with Buccolam
compared to RD are driven by a reduction in the need for ambulance call-outs and
hospital stays and, compared to UOM, through reduced drug costs and wastage.
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OBJECTIVES: To carry out a cost-minimization analysis of Fingolimod compared to
Natalizumab in the second-line treatment of Remittent-Recurrent Multiple Sclero-
sis (RRMS) in Spain. METHODS: Based on the indirect comparisons of Del Santo
2011 and Zintzaras 2012, where no significant differences between Fingolimod and
Natalizumab were observed, a cost-minimization analysis was developed for a
2-years horizon. The relapse rate (RR) applied was the same for both treatment
arms and resource use associated to Spanish costs (€2012) was modelled. The
analysis was conducted from the National Health System (NHS) perspective and a
3 % annual discount rate was applied to future costs. A Sensitivity Analysis was
performed in order to validate the robustness of the model. RESULTS: The indirect
comparison of Fingolimod with Natalizumab recorded a Confidence Interval of the
hazard ratio between 0.82 and 1.07 (p-value: NS). The pharmacological cost for a
2-years horizon was 41,107€ for Fingolimod and 42,053€ for Natalizumab. The min-
imum cost saving derived from Fingolimod prescription was of 876€, after applying
a 7.5% discount. Considering an annual mean RR of 0.22 a 43,991€ direct medical
cost was observed for Fingolimod and a 49,161€ cost for Natalizumab. Depending
on the sensitivity analysis scenarios Fingolimod generated savings of 3.2%-11%.
CONCLUSIONS: Fingolimod is an effective second-line treatment option of RRMS
compared to Natalizumab, generating savings to the NHS.
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OBJECTIVES: Parkinson disease (PD) is a chronic progressive disorder that causes
significant disability and reduces quality of life (QOL). In Europe the prevalence of
PD is 160/100 000 among those aged 65 and older, and annual direct cost associated
to this disease ranging from 5163€ to 9975€ per patient. No cure is available to stop
the disease, and an American study shows that a patient education program re-
duced disease progression, improved health confidence, reduced medication and
decreases physician visits. The aim of this study is to assess the cost-utility of a
therapeutic education program vs. traditional care in PD patients. METHODS: A
total of 120 patients of both sexes, under medication and meeting the criteria of the
UK Parkinson’s Disease Society were recruited from two neurology departments in
University Hospital of Toulouse between 2008 and 2010. The primary outcome
measure was the incremental cost-utility ratio of therapeutic education program
vs. traditional care. The primary medical outcome was the difference between
baseline and one year SF-36 v1 score transformed to utility trough a utility function
provided by Qualitymetrics®. This prospective economic analysis adopted the
health care payer’s perspective and take into account direct medical and non-
medical costs. RESULTS: Forty-five patients were excluded because they were not
found on social health insurance database. Costs and utility were adjusted on age,
sex and disease duration. Annual adjusted cost per patient was respectively 6633,
34€ (sd1250.15) in 34 patients and 6941, 17€ (sd1125.51) in 41 patients for tradi-
tional care group and therapeutic education program group (p0.86). Adjusted
difference of utility was -0,020 (sd0.019) and 0.019 (sd0.017) for traditional care
group and therapeutic education program group respectively (p0.14). Incremen-
tal cost-utility adjusted ratio was 7880.25/QALY. CONCLUSIONS: Therapeutic ed-
ucation program for Parkinson disease patients is cost-effective. Nevertheless,
these results should be confirmed with multicenter prospective studies assessing
medical and economic consequences of these strategies.
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OBJECTIVES: To assess the cost-utility of oral fingolimod versus interferon-
(IFN-) treatments (IFN--1a 30mcg, IFN--1a 22mcg, IFN--1a 44mcg and IFN--1b
300mcg) in relapsing-remitting multiple sclerosis (RRMS) patients from the Brazil-
ian Public Healthcare System perspective.METHODS: Cost-effectiveness was eval-
uated using a Markov model, in 20-years time horizon, comparing fingolimod to
IFN- treatments. Health states were based on EDSS and relapses, and included
separate states for RRMS and Secondary Progressive MS (SPMS). In each yearly
cycle, RRMS patients can discontinue treatment; remain stable, progress to higher
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